MCID: BRS015
MIFTS: 38

Breast Medullary Carcinoma

Categories: Cancer diseases, Immune diseases

Aliases & Classifications for Breast Medullary Carcinoma

MalaCards integrated aliases for Breast Medullary Carcinoma:

Name: Breast Medullary Carcinoma 12 14
Medullary Breast Carcinoma with Lymphoid Stroma 12
Medullary Carcinoma of Breast 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5605
NCIt 47 C9119
UMLS 69 C0860580

Summaries for Breast Medullary Carcinoma

MalaCards based summary : Breast Medullary Carcinoma, also known as medullary breast carcinoma with lymphoid stroma, is related to gastrointestinal tuberculosis and testicular germ cell cancer. An important gene associated with Breast Medullary Carcinoma is GZMB (Granzyme B), and among its related pathways/superpathways are Development HGF signaling pathway and Endometrial cancer. The drugs Capecitabine and Vinblastine have been mentioned in the context of this disorder. Affiliated tissues include breast, testes and lymph node, and related phenotypes are cardiovascular system and endocrine/exocrine gland

Related Diseases for Breast Medullary Carcinoma

Diseases related to Breast Medullary Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 123)
id Related Disease Score Top Affiliating Genes
1 gastrointestinal tuberculosis 10.5 FASLG GZMB
2 testicular germ cell cancer 10.4 FASLG GZMB
3 macrocephaly, mental retardation, short stature, spastic paraplegia and cns malformations 10.4 FASLG GZMB
4 paramyloidosis 10.4 FASLG GZMB
5 bolivian hemorrhagic fever 10.4 FASLG GZMB
6 acute monoblastic leukemia 10.3 FASLG GZMB
7 screw worm infectious disease 10.3 FASLG GZMB
8 immunodeficiency 11a 10.3 FASLG GZMB
9 nerve fibre bundle defect 10.3 ERBB2 ESR1
10 spondyloarthropathy 1 10.2 FASLG GZMB
11 breast sarcoma 10.2 ERBB2 ESR1
12 cutaneous lupus erythematosus 10.2 BRCA1 ERBB2
13 hip subluxation 10.2 ERBB2 ESR1
14 endocervicitis 10.2 BRCA1 ERBB2
15 intestinal disaccharidase deficiency 10.2 FASLG GZMB
16 extracranial neuroblastoma 10.2 BRCA1 ERBB2
17 fallopian tube mucinous tumor 10.1 ERBB2 ESR1
18 gastritis 10.0 ERBB2 PGR
19 bartholin's gland benign neoplasm 10.0 ESR1 PGR
20 central nervous system organ benign neoplasm 10.0 ESR1 PGR
21 gallbladder leiomyoma 10.0 ESR1 PGR
22 lung adenoma 10.0 ESR1 PGR
23 fallopian tube benign neoplasm 10.0 ESR1 PGR
24 paranasal sinus disease 10.0 ESR1 PGR
25 dartoic leiomyoma 10.0 ESR1 PGR
26 skin sarcoma 10.0 ERBB2 PGR
27 urinary bladder inverted papilloma 10.0 ESR1 PGR
28 her2-receptor negative breast cancer 10.0 ERBB2 PGR
29 deafness, autosomal dominant 8/12 10.0 ESR1 PGR
30 intestinal perforation 10.0 ESR1 PGR
31 superficial basal cell carcinoma 10.0 ESR1 PGR
32 sarcomatoid squamous cell skin carcinoma 10.0 ESR1 PGR
33 pineal region meningioma 10.0 ESR1 PGR
34 bladder colloid adenocarcinoma 10.0 ESR1 PGR
35 ovarian mesodermal adenosarcoma 10.0 ESR1 PGR
36 endophthalmitis 10.0 ESR1 PGR
37 osteogenesis imperfecta 10.0 ESR1 PGR
38 kallmann syndrome 10.0 ERBB2 PGR
39 colon neuroendocrine neoplasm 10.0 ERBB2 PGR
40 penis squamous cell carcinoma 10.0 ERBB2 PGR
41 cutaneous mucoepidermoid carcinoma 9.9 ESR1 PGR
42 holoprosencephaly 6 9.9 ESR1 PGR
43 acute thyroiditis 9.9 ESR1 PGR
44 breast fibrosarcoma 9.9 ERBB2 PGR
45 retinitis pigmentosa 20 9.9 ESR1 PGR
46 urethra clear cell adenocarcinoma 9.9 ESR1 PGR
47 rectal neoplasm 9.9 ESR1 PGR
48 adenosine monophosphate deaminase 1 deficiency 9.9 ESR1 PGR
49 perinatal jaundice due to hepatocellular damage 9.9 ESR1 PGR
50 thoracic benign neoplasm 9.9 ESR1 PGR

Graphical network of the top 20 diseases related to Breast Medullary Carcinoma:



Diseases related to Breast Medullary Carcinoma

Symptoms & Phenotypes for Breast Medullary Carcinoma

MGI Mouse Phenotypes related to Breast Medullary Carcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.88 BRCA1 ERBB2 ESR1 FASLG PGR
2 endocrine/exocrine gland MP:0005379 9.83 BRCA1 ERBB2 ESR1 FASLG PGR
3 integument MP:0010771 9.8 BRCA1 ERBB2 ESR1 FASLG PGR
4 digestive/alimentary MP:0005381 9.76 BRCA1 ERBB2 ESR1 FASLG
5 neoplasm MP:0002006 9.72 BRCA1 ERBB2 ESR1 FASLG PGR
6 limbs/digits/tail MP:0005371 9.67 BRCA1 ERBB2 ESR1 PGR
7 normal MP:0002873 9.65 FASLG PGR BRCA1 ERBB2 ESR1
8 reproductive system MP:0005389 9.55 BRCA1 ERBB2 ESR1 FASLG PGR
9 respiratory system MP:0005388 9.26 ESR1 FASLG BRCA1 ERBB2
10 skeleton MP:0005390 9.02 BRCA1 ERBB2 ESR1 FASLG PGR

Drugs & Therapeutics for Breast Medullary Carcinoma

Drugs for Breast Medullary Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 162)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Capecitabine Approved, Investigational Phase 3,Phase 2 154361-50-9 60953
2
Vinblastine Approved Phase 3,Phase 2,Phase 1 865-21-4 13342 241903
3
Vinorelbine Approved, Investigational Phase 3,Phase 2,Phase 1 71486-22-1 60780 44424639
4
Anastrozole Approved, Investigational Phase 3,Phase 2 120511-73-1 2187
5
Tamoxifen Approved Phase 3,Phase 2 10540-29-1 2733526
6
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
7
Carboplatin Approved Phase 2, Phase 3, Phase 1 41575-94-4 10339178 498142 38904
8
Paclitaxel Approved, Vet_approved Phase 2, Phase 3, Phase 1 33069-62-4 36314
9
Trastuzumab Approved, Investigational Phase 2, Phase 3, Phase 1 180288-69-1 9903
10
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
11
Epirubicin Approved Phase 3,Phase 2,Phase 1 56420-45-2 41867
12
Estradiol Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-28-2 5757
13
Fulvestrant Approved, Investigational Phase 3,Phase 2,Phase 1 129453-61-8 104741 17756771
14
Doxorubicin Approved, Investigational Phase 2, Phase 3,Phase 1 23214-92-8 31703
15
Letrozole Approved, Investigational Phase 3,Phase 2,Phase 1 112809-51-5 3902
16
Fluorouracil Approved Phase 3,Phase 1,Phase 2 51-21-8 3385
17
Exemestane Approved, Investigational Phase 3 107868-30-4 60198
18
Metformin Approved Phase 3 657-24-9 14219 4091
19
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
20
Lapatinib Approved March 2007, Investigational Phase 2, Phase 3 231277-92-2, 388082-78-8 208908 9941095
21
Doxil Approved June 1999 Phase 2, Phase 3,Phase 1 31703
22 Antimetabolites Phase 3,Phase 2,Phase 1
23 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
24 Antimitotic Agents Phase 3,Phase 2,Phase 1
25 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
26 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1
27 Aromatase Inhibitors Phase 3,Phase 2,Phase 1
28 Bone Density Conservation Agents Phase 3,Phase 2,Phase 1
29 Estrogen Antagonists Phase 3,Phase 2,Phase 1
30 Estrogen Receptor Modulators Phase 3,Phase 2
31 Estrogens Phase 3,Phase 2,Phase 1
32 Hormone Antagonists Phase 3,Phase 2,Phase 1,Early Phase 1
33 Hormones Phase 3,Phase 2,Phase 1,Early Phase 1
34 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Early Phase 1
35 Selective Estrogen Receptor Modulators Phase 3,Phase 2
36 Steroid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
37 Albumin-Bound Paclitaxel Phase 2, Phase 3, Phase 1
38 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1
39 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
40 Anti-Bacterial Agents Phase 2, Phase 3,Phase 1
41 Antibiotics, Antitubercular Phase 2, Phase 3,Phase 1
42 Protein Kinase Inhibitors Phase 2, Phase 3
43 Topoisomerase Inhibitors Phase 2, Phase 3,Phase 1
44 Estradiol 17 beta-cypionate Phase 3,Phase 2,Phase 1
45 Estradiol 3-benzoate Phase 3,Phase 2,Phase 1
46 Estradiol valerate Phase 3,Phase 2,Phase 1 979-32-8
47 Estrogen Receptor Antagonists Phase 3,Phase 2,Phase 1
48 Polyestradiol phosphate Phase 3,Phase 2,Phase 1
49 Anticoagulants Phase 3,Phase 2
50 Calcium, Dietary Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 157)

id Name Status NCT ID Phase Drugs
1 Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml® Completed NCT01448447 Phase 4
2 Study of Autologous Fat Enhanced w/ Regenerative Cells Transplanted to Reconstruct Breast Deformities After Lumpectomy Completed NCT00616135 Phase 4
3 Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer Completed NCT00742222 Phase 4
4 Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC) Unknown status NCT01126138 Phase 3 Vinorelbine plus Capecitabine for 6 cycles, followed by Capecitabine;Docetaxel plus Capecitabine for 6 cycles, followed by Capecitabine
5 Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With Active Breathing Coordinator Unknown status NCT00321048 Phase 3
6 Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer Completed NCT01112254 Phase 3
7 Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy Completed NCT00053898 Phase 3 anastrozole;tamoxifen citrate
8 Conservative Surgery With or Without Axillary Lymphnode Removal in Treating Women With T1N0 Breast Cancer Completed NCT01508546 Phase 3
9 Intraoperative Gamma Camera for Breast Cancer Surgery Completed NCT00757302 Phase 3
10 Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer Completed NCT01426880 Phase 2, Phase 3 Carboplatin;background treatment
11 Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1 Recruiting NCT02620280 Phase 3 Carboplatin;Abraxane;MPDL3280A;Anthra
12 Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery Recruiting NCT01953588 Phase 3 fulvestrant;anastrozole
13 Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Recruiting NCT01272037 Phase 3 Anastrozole;Exemestane;Letrozole;Systemic Chemotherapy;Tamoxifen Citrate
14 Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer Recruiting NCT01905046 Phase 3 metformin hydrochloride
15 Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast Active, not recruiting NCT00470236 Phase 3
16 Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Active, not recruiting NCT00769379 Phase 3
17 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms Unknown status NCT01237457 Phase 2 177Lu-DOTATATE
18 Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole Unknown status NCT00077168 Phase 2 anastrozole;tamoxifen citrate
19 Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer Unknown status NCT01891357 Phase 2 Paclitaxel;lapatinib;trastuzumab
20 "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer" Unknown status NCT01641406 Phase 2 Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab;Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab;Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab
21 Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors Unknown status NCT02150525 Phase 2
22 Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS) Unknown status NCT00669747 Phase 2 Carboplatin i.d. Days 1 & 15;Carboplatin i.d. Day 1; Normal Saline i.d. Day 15;Normal Saline
23 Radiation Therapy in Treating Women With Stage I or Stage II Breast Cancer Completed NCT00002873 Phase 1, Phase 2
24 Ten Years Results of a Score System to Address Adjuvant Therapies After Breast Conserving Surgery for Ductal Carcinoma in Situ of the Breast Completed NCT03002766 Phase 2
25 Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer Completed NCT00416403 Phase 2 fluvastatin sodium
26 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ Completed NCT00952731 Phase 2 oral placebo;afimoxifene;tamoxifen citrate;placebo gel
27 Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial) Completed NCT01023477 Phase 1, Phase 2 Chloroquine Standard Dose (500mg/week);Chloroquine Low Dose (250mg/week)
28 Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer Completed NCT00106002 Phase 2 pemetrexed
29 Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer Completed NCT00182793 Phase 2 carboplatin;cyclophosphamide;melphalan;thiotepa
30 Partial Breast Irradiation for Low-risk Ductal Carcinoma In Situ After Breast-conserving Surgery Recruiting NCT02617082 Phase 2
31 Clinical Outcome of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast Recruiting NCT02897700 Phase 1, Phase 2 Single agent of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate;cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM);Placebo
32 Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast Recruiting NCT02993159 Phase 2 Afimoxifene;Tamoxifen Citrate
33 Conjugated Estrogens/Bazedoxifene in Treating Patients With Ductal Carcinoma in Situ Undergoing Surgery Recruiting NCT02694809 Phase 2 Conjugated Estrogens/Bazedoxifene
34 Effect of High Dose Vitamin D on Cancer Biomarkers and Breast Cancer Tumors Recruiting NCT02856503 Phase 1, Phase 2 Vitamin D3
35 Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer Recruiting NCT02636582 Phase 2 Nelipepimut-S Plus GM-CSF Vaccine
36 Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery Recruiting NCT03113825 Phase 2 AVB-620
37 A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant Recruiting NCT02540330 Phase 2 Fulvestrant
38 Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Recruiting NCT02779855 Phase 1, Phase 2 Paclitaxel
39 Single Fraction Intraoperative Radiotherapy Recruiting NCT01688388 Phase 1, Phase 2
40 G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Recruiting NCT02983071 Phase 1, Phase 2 G1T38;Fulvestrant
41 Radiation Therapy in Treating Women With Early Stage Breast Cancer Recruiting NCT00909909 Phase 2
42 Denosumab as an add-on Neoadjuvant Treatment (GeparX) Recruiting NCT02682693 Phase 2 Denosumab;nab-Paclitaxel;Epirubicin;Cyclophosphamide;Carboplatin;Trastuzumab;Pertuzumab
43 Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy Recruiting NCT02314156 Phase 2 Telapristone Acetate;Telapristone Acetate
44 Radiation Therapy in Treating Women With Locally Recurrent Breast Cancer Previously Treated With Repeat Breast-Preserving Surgery Active, not recruiting NCT01082211 Phase 2
45 Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ Active, not recruiting NCT01439711 Phase 2 letrozole
46 Randomized Trial of Hypofractionated Whole Breast Irradiation Versus Conventionally Fractionated Whole Breast Irradiation for Ductal Carcinoma in Situ and Early Invasive Breast Cancer Active, not recruiting NCT01266642 Phase 2
47 Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer Active, not recruiting NCT02137252 Phase 2 Naltrexone;Sugar Pill
48 Radiation Therapy in Treating Patients With Recurrent Breast Cancer Active, not recruiting NCT00945061 Phase 2
49 Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer Active, not recruiting NCT00295893 Phase 2 carboplatin;cyclophosphamide;docetaxel;doxorubicin hydrochloride;paclitaxel
50 Docosahexaenoic Acid in Preventing Recurrence in Breast Cancer Survivors Active, not recruiting NCT01849250 Phase 2 Docosahexaenoic Acid

Search NIH Clinical Center for Breast Medullary Carcinoma

Genetic Tests for Breast Medullary Carcinoma

Anatomical Context for Breast Medullary Carcinoma

MalaCards organs/tissues related to Breast Medullary Carcinoma:

39
Breast, Testes, Lymph Node, Skin, T Cells, Thyroid, Liver

Publications for Breast Medullary Carcinoma

Articles related to Breast Medullary Carcinoma:

id Title Authors Year
1
Immunoglobulin repertoire of B lymphocytes infiltrating breast medullary carcinoma. ( 15156099 )
2003
2
A scFv phage display mini library generated from the immunoglobulin repertoire of breast medullary carcinoma infiltrating B lymphocytes. ( 11360824 )
2000
3
Immunoglobulin variable regions usage by B-lymphocytes infiltrating a human breast medullary carcinoma. ( 10065736 )
1999
4
E-cadherin and beta-catenin expression in breast medullary carcinomas. ( 10402239 )
1999

Variations for Breast Medullary Carcinoma

Cosmic variations for Breast Medullary Carcinoma:

9 (show all 19)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM775 PIK3CA breast,NS,carcinoma,medullary c.3140A>G p.H1047R 12
2 COSM763 PIK3CA breast,NS,carcinoma,medullary c.1633G>A p.E545K 12
3 COSM10654 TP53 breast,NS,carcinoma,medullary carcinoma c.637C>T p.R213* 11
4 COSM10834 TP53 breast,NS,carcinoma,medullary carcinoma c.711G>A p.M237I 11
5 COSM10648 TP53 breast,NS,carcinoma,medullary carcinoma c.524G>A p.R175H 11
6 COSM43947 TP53 breast,NS,carcinoma,medullary carcinoma c.614A>G p.Y205C 11
7 COSM10646 TP53 breast,NS,carcinoma,medullary carcinoma c.725G>A p.C242Y 11
8 COSM10662 TP53 breast,NS,carcinoma,medullary carcinoma c.743G>A p.R248Q 11
9 COSM10728 TP53 breast,NS,carcinoma,medullary carcinoma c.839G>A p.R280K 11
10 COSM10742 TP53 breast,NS,carcinoma,medullary carcinoma c.578A>G p.H193R 11
11 COSM10731 TP53 breast,NS,carcinoma,medullary carcinoma c.707A>G p.Y236C 11
12 COSM44687 TP53 breast,NS,carcinoma,medullary carcinoma c.379T>C p.S127P 11
13 COSM10758 TP53 breast,NS,carcinoma,medullary carcinoma c.659A>G p.Y220C 11
14 COSM11286 TP53 breast,NS,carcinoma,medullary carcinoma c.1015G>T p.E339* 11
15 COSM10667 TP53 breast,NS,carcinoma,medullary carcinoma c.646G>A p.V216M 11
16 COSM10893 TP53 breast,NS,carcinoma,medullary carcinoma c.824G>A p.C275Y 11
17 COSM11089 TP53 breast,NS,carcinoma,medullary carcinoma c.584T>C p.I195T 11
18 COSM11148 TP53 breast,NS,carcinoma,medullary carcinoma c.476C>T p.A159V 11
19 COSM10726 TP53 breast,NS,carcinoma,medullary carcinoma c.856G>A p.E286K 11

Expression for Breast Medullary Carcinoma

Search GEO for disease gene expression data for Breast Medullary Carcinoma.

Pathways for Breast Medullary Carcinoma

Pathways related to Breast Medullary Carcinoma according to GeneCards Suite gene sharing:

(show all 12)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.38 ERBB2 ESR1 FASLG
2
Show member pathways
11.98 BRCA1 ERBB2 ESR1 PGR
3 11.74 ERBB2 ESR1 FASLG
4
Show member pathways
11.58 BRCA1 ESR1 PGR
5 11.31 BRCA1 ERBB2
6
Show member pathways
11.26 FASLG GZMB
7 11.24 BRCA1 ERBB2
8
Show member pathways
11.17 ERBB2 ESR1 PGR
9 11.14 BRCA1 FASLG
10
Show member pathways
11.07 BRCA1 ESR1
11
Show member pathways
10.97 FASLG GZMB
12 10.66 BRCA1 ERBB2 FASLG

GO Terms for Breast Medullary Carcinoma

Biological processes related to Breast Medullary Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 regulation of transcription, DNA-templated GO:0006355 9.55 BRCA1 ERBB2 ESR1 FASLG PGR
2 transcription, DNA-templated GO:0006351 9.35 BRCA1 ERBB2 ESR1 FASLG PGR
3 response to estrogen GO:0043627 9.32 BRCA1 ESR1
4 steroid hormone mediated signaling pathway GO:0043401 9.26 ESR1 PGR
5 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 8.62 BRCA1 FASLG

Molecular functions related to Breast Medullary Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.33 BRCA1 ESR1 PGR
2 ATPase binding GO:0051117 9.32 ESR1 PGR
3 steroid hormone receptor activity GO:0003707 9.26 ESR1 PGR
4 RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding GO:0004879 8.96 ESR1 PGR
5 steroid binding GO:0005496 8.62 ESR1 PGR

Sources for Breast Medullary Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....